Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 175 participants.

Also called NCT05459688

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 175 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05459688
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05459688. Allocation not applicable; no masking; primary purpose treatment. Start 2022-04-06 (actual); primary completion 2023-11-07 (actual). Results posted on 2024-12-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124
Condition
Hypertension
Intervention (Drug)
CIN-107
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct05459688
Content hash
9e9c801b9194d872b42b411104edb7b45f56a2c99a60a1fd8ee6a268ea044946